floxuridine has been researched along with Hypoxia in 6 studies
Floxuridine: An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection; when administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.
floxuridine : A pyrimidine 2'-deoxyribonucleoside compound having 5-fluorouracil as the nucleobase; used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.
Hypoxia: Sub-optimal OXYGEN levels in the ambient air of living organisms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study utilized the imaging data of primary liver cancer (PLC) treated with floxuridine (FUDR) and bevacizumab to test the hypothesis that dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) parameters correlate with tissue hypoxia markers and treatment outcome." | 5.15 | Antiangiogenic therapy for primary liver cancer: correlation of changes in dynamic contrast-enhanced magnetic resonance imaging with tissue hypoxia markers and clinical response. ( Allen, PJ; Bamboat, Z; D'Angelica, MI; DeMatteo, RP; Fong, Y; Gönen, M; Gultekin, DH; Haviland, D; Jarnagin, WR; Kemeny, N; Schwartz, LH; Shia, J; Yopp, AC, 2011) |
| "Floxuridine oligomers are anticancer oligonucleotide drugs composed of a number of floxuridine residues." | 1.62 | Floxuridine Oligomers Activated under Hypoxic Environment. ( Ishinabe, T; Morihiro, K; Okamoto, A; Osawa, T; Osumi, H; Takatsu, M, 2021) |
| "Furthermore, the fog-2(q71) long-term anoxia survival phenotype was suppressed when oocyte maturation and ovulation were induced by mating with males that have functional or nonfunctional sperm." | 1.35 | Reduction in ovulation or male sex phenotype increases long-term anoxia survival in a daf-16-independent manner in Caenorhabditis elegans. ( LeBlanc, MG; Mendenhall, AR; Mohan, DP; Padilla, PA, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (16.67) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Peng, X | 1 |
| Gao, J | 1 |
| Yuan, Y | 1 |
| Liu, H | 1 |
| Lei, W | 1 |
| Li, S | 1 |
| Zhang, J | 1 |
| Wang, S | 1 |
| Morihiro, K | 1 |
| Ishinabe, T | 1 |
| Takatsu, M | 1 |
| Osumi, H | 1 |
| Osawa, T | 1 |
| Okamoto, A | 1 |
| Weiss, JT | 1 |
| Carragher, NO | 1 |
| Unciti-Broceta, A | 1 |
| Mendenhall, AR | 1 |
| LeBlanc, MG | 1 |
| Mohan, DP | 1 |
| Padilla, PA | 1 |
| Yopp, AC | 1 |
| Schwartz, LH | 1 |
| Kemeny, N | 1 |
| Gultekin, DH | 1 |
| Gönen, M | 1 |
| Bamboat, Z | 1 |
| Shia, J | 1 |
| Haviland, D | 1 |
| D'Angelica, MI | 1 |
| Fong, Y | 1 |
| DeMatteo, RP | 1 |
| Allen, PJ | 1 |
| Jarnagin, WR | 1 |
1 review available for floxuridine and Hypoxia
| Article | Year |
|---|---|
Radiation sensitizers.
Topics: Animals; Antineoplastic Agents; Bromodeoxycytidine; Bromodeoxyuridine; Carcinoma; Deoxyuridine; Dogs | 1976 |
1 trial available for floxuridine and Hypoxia
| Article | Year |
|---|---|
Antiangiogenic therapy for primary liver cancer: correlation of changes in dynamic contrast-enhanced magnetic resonance imaging with tissue hypoxia markers and clinical response.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antigens, Neopl | 2011 |
4 other studies available for floxuridine and Hypoxia
| Article | Year |
|---|---|
Hypoxia-Activated and Indomethacin-Mediated Theranostic Prodrug Releasing Drug On-Demand for Tumor Imaging and Therapy.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Hepatocellular; Cell Proliferation; | 2019 |
Floxuridine Oligomers Activated under Hypoxic Environment.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Floxuridine; Humans; Hypoxia; Mice, Inbr | 2021 |
Palladium-mediated dealkylation of N-propargyl-floxuridine as a bioorthogonal oxygen-independent prodrug strategy.
Topics: Antineoplastic Agents; Cell Line, Tumor; Dealkylation; Drug Screening Assays, Antitumor; Floxuridine | 2015 |
Reduction in ovulation or male sex phenotype increases long-term anoxia survival in a daf-16-independent manner in Caenorhabditis elegans.
Topics: Animals; Antimetabolites, Antineoplastic; Caenorhabditis elegans; Caenorhabditis elegans Proteins; F | 2009 |